DelveInsight’s comprehensive analysis of the global Migraine pipeline reveals the active involvement of over 30 key companies in developing more than 30 treatment therapies for Migraine. The “Migraine Pipeline Insight, 2023” report offers a detailed evaluation of the pipeline products, ranging from pre-clinical phases to market availability, providing insights into clinical trials, mechanisms of action, routes of administration, and advancements in the field.
Notable companies such as Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, AEON Biopharma, Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, and Pfizer are all contributing to the development of novel therapies for Migraine treatment. Emerging therapies like PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, and Zavegepant, among others, hold promise to make a substantial impact on the Migraine market.
A significant highlight is Click Therapeutics, Inc.’s ReMMiD-C study, a fully remote and decentralized clinical trial aiming to assess the effectiveness and safety of digital therapeutics in reducing monthly migraine days for adults with episodic migraine.
Nexalin Technology, Inc. has reported promising clinical data for its Gen-2 neurostimulation device, showcasing potential therapeutic benefits for patients with migraine headaches. Axsome Therapeutics, Inc. is resubmitting its New Drug Application for AXS-07 in the acute treatment of migraine following a productive meeting with the U.S. FDA. They have also initiated an open-label study to evaluate the effectiveness and safety of AXS-07 for patients with a prior inadequate response to an oral CGRP inhibitor.
DelveInsight’s report underscores the collective efforts of companies in advancing migraine treatment therapies, signifying a positive trajectory in the battle against this debilitating condition. As the field continues to evolve, these developments hold the promise of providing relief and improved quality of life for those affected by migraines.
